Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review

被引：7
|
作者：
Arbit, Boris [1 ]
Hsu, Jonathan C. [1 ]
机构：
[1] Univ Calif San Diego, Dept Med, Div Cardiol, Cardiac Electrophysiol Sect, La Jolla, CA 92093 USA
来源：
CLINICAL CARDIOLOGY | 2015年 / 38卷 / 11期
关键词：
PROTHROMBIN COMPLEX CONCENTRATE; DIRECT THROMBIN INHIBITOR; ACUTE ISCHEMIC-STROKE; PARTIAL THROMBOPLASTIN TIME; RECOMBINANT FACTOR VIIA; FACTOR XA INHIBITOR; DABIGATRAN ETEXILATE; IN-VITRO; LABORATORY MEASUREMENT; COAGULATION ASSAYS;
D O I：
10.1002/clc.22434
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Atrial fibrillation (AF) is the most common cardiac arrhythmia and predisposes patients to an increased risk of embolic stroke. After nearly 60 years, warfarin is no longer the only effective therapeutic option for patients with AF. Large randomized trials have consistently shown that non- vitamin K oral anticoagulants (NOACs) including dabigatran, rivaroxaban, apixaban, and edoxaban significantly reduce from the risk of intracranial hemorrhage (ICH) compared with warfarin. We provide a focused review regarding the NOACs and ICH in AF patients by summarizing findings of these large clinical trials, mechanisms of lower ICH, reversal strategies with specific agents, and monitoring strategies.
引用
收藏
页码：684 / 691
页数：8
相关论文
共 50 条
  • [1] Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation A Review
    Eikelboom, John W.
    Quinlan, Daniel J.
    Hirsh, Jack
    Connolly, Stuart J.
    Weitz, Jeffrey I.
    JAMA CARDIOLOGY, 2017, 2 (05) : 566 - 574
  • [2] Non-Vitamin K Antagonist Oral Anticoagulant for Atrial Fibrillation in Obese Patients
    Wang, Stephen Y.
    Giugliano, Robert P.
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 127 : 176 - 183
  • [3] Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction
    Khan, Ahsan A.
    Lip, Gregory Y. H.
    ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (23)
  • [4] Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction
    Yao, Xiaoxi
    Shah, Nilay D.
    Sangaralingham, Lindsey R.
    Gersh, Bernard J.
    Noseworthy, Peter A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (23) : 2779 - 2790
  • [5] Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients
    Larsen, Torben Bjerregaard
    EUROPACE, 2015, 17 (02): : 169 - 170
  • [6] Characteristics of Symptomatic Intracranial Hemorrhage in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulant Therapy
    Akiyama, Hisanao
    Uchino, Kenji
    Hasegawa, Yasuhiro
    PLOS ONE, 2015, 10 (07):
  • [7] Use of non-vitamin K antagonist oral anticoagulants in frail patients with atrial fibrillation
    Ortigoza, Daniel, V
    Valentino, Mariana
    REVISTA DE LA FEDERACION ARGENTINA DE CARDIOLOGIA, 2021, 50 (02): : 43 - 48
  • [8] Adherence to oral anticoagulant therapy in patients with atrial fibrillation Focus on non-vitamin K antagonist oral anticoagulants
    Raparelli, Valeria
    Proietti, Marco
    Cangemi, Roberto
    Lip, Gregory Y. H.
    Lane, Deirdre A.
    Basili, Stefania
    THROMBOSIS AND HAEMOSTASIS, 2017, 117 (02) : 209 - 218
  • [9] Association of Vitamin K and Non-Vitamin K Oral Anticoagulant Use and Cancer Incidence in Atrial Fibrillation Patients
    Iftimi, Adina A.
    Rodriguez-Bernal, Clara L.
    Peiro, Salvador
    Bonanad, Santiago
    Ferrero-Gregori, Andreu
    Hurtado, Isabel
    Garcia-Sempere, Anibal
    Sanfelix-Gimeno, Gabriel
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (01) : 200 - 208
  • [10] Costs of minor bleeds in atrial fibrillation patients using a non-vitamin K antagonist oral anticoagulant
    Mitrovic, Darko
    Plomp, Marlies
    Folkeringa, Richard
    Veeger, Nic
    Feenstra, Talitha
    van Roon, Eric
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (09) : 1461 - 1466
12345